Polysomnography (PSG) Device Segment to dominate North America Sleep Apnea Diagnostics Market during 2021–2028

According to a new market research study on “North America Sleep Apnea Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product and End User,” is expected to reach US$ 259.45 million by 2028 from US$ 177.12 million in 2021. The market is estimated to grow at a CAGR of 5.6% from 2021 to 2028. The report provides trends prevailing in the North America sleep apnea diagnostics market along with the drivers and restraints pertaining to the market growth. Growing geriatric population, elevating government support for medical technologies, and advanced prevalence of sleep apnea are the major factor driving the growth of the North America sleep apnea diagnostics market. However, higher cost of diagnosis of sleep apnea hinder the growth of North America sleep apnea diagnostics market.

North American region is highly affected due to the outbreak of the Covid-19 pandemic. Countries such as the US and Canada reported the highest numbers of COVID-19 positive cases. The US-registered highest number of deaths due to the COVID-19 pandemic. The chaotic situation was created in the medical industry across the countries, increased demand for diagnosing and therapeutic devices have dramatically increased in the hospitals. For instance, demand for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in the hospitals across the countries. On the other hand, demand for personal protective kits has significantly gone up. The FDA has increased its efforts to support the health of people and has imposed several guidelines and for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. So increased demand in other categories have considerably hamper the sleep apnea diagnostics market. Thus, market is likely to be slower in COVID-19.

The North America sleep apnea diagnostics market is segmented on the basis of product, end user, and country. Based on product, the market is segmented into polysomnography (PSG) device, home sleep testing devices, oximeter, actigraphy monitoring device, and sleep apnea screening device. In 2021, polysomnography (PSG) device segment held the largest share in the market, and oximeter is expected to be the fastest growing segment during the forecast period. Further based on oximeter, the market is segmented into finger tip oximeter, handheld oximeter, wrist-worn oximeter, and tabletop oximeter. In 2021, finger tip oximeter segment held the largest share in the market, and it is also expected to be the fastest growing segment during the forecast period. Based on end user, the market is bifurcated into hospitals and sleep laboratories and home care settings. In 2021, hospitals and sleep laboratories segment held the largest share in the market, and home care settings is expected to be the fastest growing segment during the forecast period. Similarly Based on country the market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest share in the market, and it is also expected to be the fastest growing country during the forecast period.

ResMed, Inc.; Nihon Kohden Corporation LLC; SOMNOmedics GmbH; Cleveland Medical Devices Inc.; Koninklijke Philips N.V.; Natus Medical Incorporated; Itamar Medical Ltd.; Compumedics Limited; Drive DeVilbiss International; and Cadwell Industries Inc. are among the leading companies in the North America sleep apnea diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, Philips received authorization from the US Food and Drug Administration (FDA) for the rework of the affected first-generation Dream Station devices.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com